TopPodcast.com
Menu
  • Home
  • Top Charts
  • Top Networks
  • Top Apps
  • Top Independents
  • Top Podfluencers
  • Top Picks
    • Top Business Podcasts
    • Top True Crime Podcasts
    • Top Finance Podcasts
    • Top Comedy Podcasts
    • Top Music Podcasts
    • Top Womens Podcasts
    • Top Kids Podcasts
    • Top Sports Podcasts
    • Top News Podcasts
    • Top Tech Podcasts
    • Top Crypto Podcasts
    • Top Entrepreneurial Podcasts
    • Top Fantasy Sports Podcasts
    • Top Political Podcasts
    • Top Science Podcasts
    • Top Self Help Podcasts
    • Top Sports Betting Podcasts
    • Top Stocks Podcasts
  • Podcast News
  • About Us
  • Podcast Advertising
  • Contact
Not in our directory?
Add Show Here
Podcast Equipment
Center

toppodcastlogoOur TOPPODCAST Picks

  • Comedy
  • Crypto
  • Sports
  • News
  • Politics
  • True Crime
  • Business
  • Finance

Follow Us

toppodcastlogoStay Connected

    View Top 200 Chart
    Back to Rankings Page
    Life Sciences

    BiotechTV – News

    This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

    Advertise

    Copyright: © BiotechTV

    • Apple Podcasts
    • Google Play
    • Spotify
    Latest Episodes:
    From London: iOnctura is developing its allosteric PI3Kδ for uveal melanoma - an indication that has seen progress but still has much unmet need Mar 19, 2026
    Show notes

    From Syncona's Capital Markets Day, Founder and CEO Catherine Pickering walks us through the science of roginolisib and describes the current landscape for uveal melanoma. She discusses her phase 2, which is approaching a key readout.

    From London: Spur Therapeutics is an a phase 3 for its gene therapy for Gaucher Disease - using a unique construct that allows them to have a lower dose than other gene therapies Mar 19, 2026
    Show notes

    CEO Michael Parini describes the science behind how Spur's gene therapies have two key differences compared to others, including a proprietary capsid. He discusses phase 1/2 data that has already been announced, and how he thinks about the phase 3.

    From London: Beacon Therapeutics has a phase 3 trial scheduled to read this year for its gene therapy for X-Linked Retinitis Pigmentosa (XLRP) Mar 19, 2026
    Show notes

    From Syncona's Capital Markets Day, CEO Lance Baldo describes the trial's design and the degree to which Beacon will be trying to restore vision for these patients.

    From London: Syncona CEO Chris Hollowood discusses the firm's public and private funds, and the state of investing in life sciences today from the firm's Capital Markets Day Mar 19, 2026
    Show notes

    He talks about Syncona's listed fund, and clarifies the details of a return of capital strategy for some shareholders, and he describes the strategy of the firm's new private fund. Plus, how Syncona thinks about opportunities in life sciences today.

    Checking in with Menlo Ventures' Partner Greg Yap to get his take on the latest trends in AI in healthcare Mar 18, 2026
    Show notes

    He his take on topics such as how the Baby KJ news is allowing investors and companies to think about scaling bespoke therapies, how AI might start to impact the clinical trial side of our business, and why he sees pharma adoption of AI as being important.

    Earli, which raised $105M in two rounds, is developing 'Cancer-Activated Promoters' that are set off by cancer-specific transcription factors and turn tumor cells into therapeutic payload factories Mar 17, 2026
    Show notes

    Co-Founder & CEO Cyriac Roeding and Co-Founder & CSO David Suhy describe the science behind this approach and explain how AI is helping they move closer to the clinic. The first IND filing is scheduled to be late '26 or early '27.

    Barclays Miami: MannKind CEO Michael Castagna shares an update on the company, including a recent $360M acquisition, and two regulatory reviews at FDA that have decision dates over the coming months Mar 11, 2026
    Show notes

    He describes learnings from Afrezza's commercialization, why the company acquired scPharmaceuticals, an update on their partnership with United Therapeutics in PAH, and a key IPF asset that is in the pipeline.

    Barclays Miami: Barclays' Senior Biotech Analyst Etzer Darout shares his take on biotech and discusses companies he covers that have been in the news Mar 11, 2026
    Show notes

    He comments on Abivax, Corvus, Iovance, Legend, Terns, and more.

    Barclays Miami: Zealand Pharma CEO Adam Steensberg makes the case for last week's amylin data Mar 11, 2026
    Show notes

    He argues that investors are too focused on each percentage of weight loss and not focused enough on the tolerability of new options. He discusses the timeline for the phase 3 that will likely start later this year, and how it might look different than the phase 2 study that just read out.

    Barclays Miami: Barclays' Head of Healthcare M&A shares his take on the current environment of dealmaking Mar 11, 2026
    Show notes

    Maneet Singh says that pharma companies need to keep buying, and have the financial wherewithal to do it. He also gives thoughts on which areas within biotech could attract the most interest.

    Previous 1 8 9 10 11 12 49 Next

    Related Podcasts

    Science Friday

    1

    Science Friday Astronomy
    The Naked Scientists Podcast

    2

    The Naked Scientists Podcast Life Sciences
    Stuff To Blow Your Mind

    3

    Stuff To Blow Your Mind Life Sciences
    Stuff To Blow Your Mind

    4

    Stuff To Blow Your Mind Life Sciences
    Brain Science with Ginger Campbell, MD: Neuroscience for Everyone

    5

    Brain Science with Ginger Campbell, MD: Neuroscience for Everyone Health & Fitness
    All In The Mind

    6

    All In The Mind Government & Organizations
    footer-logo

    Contact Us

    Toll Free: 844-670-7747

    Links

    • Home
    • Top Charts
    • Networks
    • Apps
    • Independents Podcasts
    • Podcast Advertising
    • Podcast News
    • Contact Us
    • About Us
    • Analytics & Insights

    Stay Connected

      Privacy, Terms of Use & Our Code of Ethics Protecting Content Creators Copyrights